Genome Sequencing
基因组测序
基本信息
- 批准号:10245046
- 负责人:
- 金额:$ 21.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-15 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
PROJECT SUMMARY
Next generation sequencing is now a central tool in the analysis of signaling pathways important in
development and disease. The Genome Sequencing Core (GSC) is aimed at providing researchers at the
University of Kansas and the state of Kansas with next-generation sequencing technologies as well as
expertise in experimental design and analysis of sequence data. Projects in the GSC include whole genome
assembly, genome re-sequencing for identification of mutations important in development and disease,
transcriptome analysis (RNA seq), variant mapping and genotyping, and identification of transcription factor
interaction sites using chromatin immunoprecipitation combined with DNA sequencing (ChIP seq). The GSC
houses an Illumina Hiseq 2500 sequencer and a MiSeq sequencer with dedicated processor and storage
space to run the instrument.
This core facility has enhanced the genomics infrastructure already at KU, in the KU Genomics Center and
the KU DNA Sequencing Facility, which provides standard, first generation sequencing. Together, the three
cores allow for a thorough, integrated dissection of disease pathways using novel fluorescence probes to
define a cellular process, to find mutations affecting that cellular process, and to define genes involved in the
cellular process. The novel approach of the CMADP is to combine the enabling technologies of fluorescent
probe synthetic chemistry and next generation sequencing to set up a pipeline for target discovery in disease
pathways.
Next generation sequencing is an enabling technology in that it has the power to allow investigators from
many different disciplines to ask new questions in their research areas of interest. The GSC enables genomics
research at the University of Kansas by eliminating the barriers of cost and communication involved with using
off-campus facilities. Interest in next generation sequencing at the University of Kansas is high, and includes
investigators in the Pharmacy School, the Department of Molecular Biosciences, and the Department of
Ecology and Evolutionary Biology. Use of the GSC will be by Projects in the COBRE Center for Molecular
Analysis of Disease Pathways, as well as by researchers across the State of Kansas and in many different
disciplines.
项目摘要
现在,下一代测序是分析信号通路的中心工具
发展与疾病。基因组测序核心(GSC)旨在为研究人员提供
堪萨斯大学和堪萨斯州采用下一代测序技术以及
实验设计和序列数据分析方面的专业知识。 GSC中的项目包括整个基因组
组装,重新测序以鉴定在发育和疾病中重要的突变,
转录组分析(RNA SEQ),变体映射和基因分型以及转录因子的鉴定
使用染色质免疫沉淀与DNA测序(CHIP SEQ)结合的相互作用位点。 GSC
设有一个Illumina Hiseq 2500音序器和带有专用处理器和存储的Miseq Sequencer
运行乐器的空间。
该核心设施增强了KU,KU基因组中心和
KU DNA测序设施提供了标准的第一代测序。在一起,三个
核心允许使用新型的荧光探针对疾病途径进行彻底的,整合的解剖
定义一个细胞过程,以找到影响细胞过程的突变,并定义涉及的基因
细胞过程。 CMADP的新方法是结合荧光的能力技术
探针合成化学和下一代测序,以建立疾病目标发现的管道
途径。
下一代测序是一种使技术,因为它有能力允许调查人员
许多不同的学科在他们感兴趣的研究领域提出新问题。 GSC启用基因组学
通过消除使用的成本和沟通障碍,在堪萨斯大学的研究
校外设施。堪萨斯大学对下一代测序的兴趣很高,其中包括
药房,分子生物科学系和部门的研究人员
生态和进化生物学。 GSC的使用将是通过鞋底分子中心的项目进行的
疾病途径以及堪萨斯州和许多不同不同的研究人员分析
学科。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Erik A Lundquist的其他基金
Regulation of directed neuroblast migration by the ECM and MAB-5/Hox
ECM 和 MAB-5/Hox 对定向神经母细胞迁移的调节
- 批准号:1046998210469982
- 财政年份:2020
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
Regulation of directed neuroblast migration by the ECM and MAB-5/Hox
ECM 和 MAB-5/Hox 对定向神经母细胞迁移的调节
- 批准号:1068933710689337
- 财政年份:2020
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
Regulation of directed neuroblast migration by the ECM and MAB-5/Hox
ECM 和 MAB-5/Hox 对定向神经母细胞迁移的调节
- 批准号:1025054910250549
- 财政年份:2020
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
Using RNA-seq to identify Hox transcriptional targets in neuronal migration
使用 RNA-seq 识别神经元迁移中的 Hox 转录靶标
- 批准号:80159058015905
- 财政年份:2010
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
Using RNA-seq to identify Hox transcriptional targets in neuronal migration
使用 RNA-seq 识别神经元迁移中的 Hox 转录靶标
- 批准号:81038138103813
- 财政年份:2010
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
CYTOSKELETAL SIGNALING AND AXON GUIDANCE
细胞骨架信号传导和轴突引导
- 批准号:64909896490989
- 财政年份:2001
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
Cytoskeletal Signaling and Axon Guidance
细胞骨架信号传导和轴突引导
- 批准号:78124267812426
- 财政年份:2001
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
Cytoskeletal Signaling and Axon Guidance
细胞骨架信号传导和轴突引导
- 批准号:69701146970114
- 财政年份:2001
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
相似国自然基金
髋关节撞击综合征过度运动及机械刺激动物模型建立与相关致病机制研究
- 批准号:82372496
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
利用碱基编辑器治疗肥厚型心肌病的动物模型研究
- 批准号:82300396
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
利用小型猪模型评价动脉粥样硬化易感基因的作用
- 批准号:32370568
- 批准年份:2023
- 资助金额:50.00 万元
- 项目类别:面上项目
丁苯酞通过调节细胞异常自噬和凋亡来延缓脊髓性肌萎缩症动物模型脊髓运动神经元的丢失
- 批准号:82360332
- 批准年份:2023
- 资助金额:31.00 万元
- 项目类别:地区科学基金项目
APOBEC3A驱动膀胱癌发生发展的动物模型及其机制研究
- 批准号:82303057
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
相似海外基金
Childhood trauma, hippocampal function, and anhedonia among those at heightened risk for psychosis
精神病高危人群中的童年创伤、海马功能和快感缺失
- 批准号:1082528710825287
- 财政年份:2024
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
Novel application of pharmaceutical AMD3100 to reduce risk in opioid use disorder: investigations of a causal relationship between CXCR4 expression and addiction vulnerability
药物 AMD3100 降低阿片类药物使用障碍风险的新应用:CXCR4 表达与成瘾脆弱性之间因果关系的研究
- 批准号:1067806210678062
- 财政年份:2023
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
Mechanisms of Metal Ion Homeostasis of Oral Streptococci
口腔链球菌金属离子稳态机制
- 批准号:1068095610680956
- 财政年份:2023
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
Design and testing of a novel circumesophageal cuff for chronic bilateral subdiaphragmatic vagal nerve stimulation (sVNS)
用于慢性双侧膈下迷走神经刺激(sVNS)的新型环食管套囊的设计和测试
- 批准号:1070212610702126
- 财政年份:2023
- 资助金额:$ 21.02万$ 21.02万
- 项目类别:
Project 2: Informing oral nicotine pouch regulations to promote public health
项目 2:告知口服尼古丁袋法规以促进公共卫生
- 批准号:1066606810666068
- 财政年份:2023
- 资助金额:$ 21.02万$ 21.02万
- 项目类别: